Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG:CCS13
- Development stage
- Preclinical
- Lead developer
- D5Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
PEG:CCS13 is a PEGylated single-stranded DNA aptamer developed by D5 Pharma that acts as a selective agonist for the CD200 receptor 1 (CD200R1). CD200R1 is an inhibitory glycoprotein receptor expressed on the surface of various immune cells, including myeloid cells and T-lymphocytes, which plays a key role in downregulating inflammatory responses. By mimicking the natural ligand CD200, PEG:CCS13 activates the receptor to suppress the induction of cytotoxic T-lymphocytes (CTLs) and inhibit the production of pro-inflammatory cytokines. The drug consists of the CCS13 DNA aptamer sequence covalently linked to a 20-kDa polyethylene glycol (PEG) chain at the 5' end to improve its pharmacokinetic properties. Its mechanism of action is distinct from traditional anti-TNF therapies, potentially offering a new therapeutic pathway for patients with rheumatoid arthritis and other inflammatory conditions.
- Other names
- PEGylated CD200R1 DNA aptamerPEGylated single-stranded DNA aptamer CCS13
02
Targets
CD200R1 (CD200 receptor 1)
Beyond the preview
Go deeper on PEG:CCS13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEG:CCS13.